3-(4-benzylcyclohexyl)-1-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)propan-1-one | 1026399-42-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: 3-(4-benzylcyclohexyl)-1-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)propan-1-one
• CAS: 1026399-42-7
• 化学式: C₂₆H₃₃NO₂S
• 分子量: 423.6
• InChiKey: WERARKTYJZLEHX-UHFFFAOYSA-N

物化性质

• 沸点：
  606.9±55.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
  申请人：——

  公开号：US20040229781A1

  公开（公告）日：2004-11-18

  The present invention provides a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject, a method for treating or preventing exercise-induced cardiac arrhythmia in a subject, and a method for preventing exercise-induced sudden cardiac death in a subject. Also provided are uses of JTV-519 in these methods. The present invention further provides methods for identifying agents for use in preventing exercise-induced sudden cardiac death, as well as agents identified by such methods. Also provided are methods for preventing exercise-induced sudden cardiac death by administering these agents. Additionally, the present invention provides methods for synthesizing JTV-519, radio-labeled JTV-519, and 1,4-benzothiazepine intermediates and derivatives.

  本发明提供了一种限制或预防受试者中RyR2-结合FKBP12.6水平下降的方法，一种治疗或预防受试者运动引起的心律失常的方法，以及一种预防受试者运动引起的猝死的方法。此外，本发明还提供了JTV-519在这些方法中的用途。本发明还提供了一种用于识别用于预防运动引起的猝死的药剂的方法，以及由这些方法识别出的药剂。此外，本发明还提供了通过给予这些药剂预防运动引起的猝死的方法。此外，本发明还提供了合成JTV-519，放射性标记的JTV-519以及1,4-苯并噻唑中间体和衍生物的方法。
• NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)
  申请人：Marks Andrew Robert

  公开号：US20100152440A1

  公开（公告）日：2010-06-17

  The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

  本发明提供了新颖的1,4-苯并噻唑啉中间体和衍生物，以及合成这些化合物的方法和检测这些化合物的方法。本发明还提供了使用这些新化合物限制或预防受试者中RyR2-结合FKBP12.6水平下降的方法；预防受试者运动引起的突发性心脏死亡的方法；以及治疗或预防受试者心力衰竭、心房颤动或运动引起的心脏心律失常的方法。本发明还提供了用于识别增强RyR2和FKBP12.6结合的试剂的方法和由这些方法识别的试剂。此外，本发明还提供了用于识别用于治疗或预防心力衰竭、心房颤动或运动引起的心脏心律失常以及预防运动引起的突发性心脏死亡的试剂的方法，以及由这些方法识别的试剂。
• US7393652B2
  申请人：——

  公开号：US7393652B2

  公开（公告）日：2008-07-01
• US7544678B2
  申请人：——

  公开号：US7544678B2

  公开（公告）日：2009-06-09
• US7718644B2
  申请人：——

  公开号：US7718644B2

  公开（公告）日：2010-05-18